Blackstone closed the week at $136.66 — down 4.7% — while sell-side analysts were busy lifting their price targets, creating an unusual divergence between Street conviction and near-term price action.
The analyst angle is the standout this week. Oppenheimer's Christopher Kotowski raised his target to $171 from $140 on August 27, maintaining an Outperform — a 22% lift that takes his target well above the current price. That follows a cluster of upgrades after the July earnings print, when Goldman Sachs, RBC Capital, TD Cowen, and Barclays all moved targets higher. The consensus mean now sits at $144, implying about 5% upside from current levels. The split between bulls and bears remains pronounced. Optimists point to Blackstone's fundraising track record, retail democratisation of alternatives, and a growing AI-infrastructure real-assets pipeline. Bears flag near-term softness in credit and real estate management fees, elevated redemptions, and a first-half 2026 fee base expected to be below the second-half recovery analysts are pencilling in. Goldman Sachs maintained its Neutral rating even as it raised the target to $127 — a reminder that not every analyst hiking targets is upgrading conviction. Valuation has re-rated modestly over the past month: the price-to-book has climbed about 10% over 30 days to 12.1x, and trailing PE has moved up nearly 9% to around 20.6x, suggesting the multiple has expanded even as the stock pulled back this week.
Positioning tells a less alarming story than the price move implies. Short interest has continued its retreat, now at 2.9% of the free float — down 12% over the past week and continuing the trend flagged in the prior note from August 26. Borrow availability remains extraordinarily loose at over 2,050%, meaning more than twenty shares are available for every one currently lent out. Cost to borrow has crept higher, up roughly 20% over the past week to 0.45%, but that remains a negligible rate compared to genuinely contested names. Short sellers are not building fresh positions into this dip. Options positioning carries more caution: the put/call ratio is running at 1.39, about 1.5 standard deviations above its 20-day average of 1.32. That's elevated but not extreme — the 52-week high is 1.87 — and reads more as routine hedging than a directional bet against the stock. Overall, the borrow market looks relaxed and short interest is retreating, while options traders are modestly more defensive than usual.
The sector-wide selloff provides important context. KKR fell 3% on the day, Carlyle dropped 3.8%, Ares lost 2.8%, and TPG gave up 3.2%. Blackstone's 4.6% single-day decline was steeper than most, though Hamilton Lane and StepStone fell 5.4% and 4.9% respectively. The alternative asset manager group broadly repriced on the day, which makes it harder to read Blackstone's weakness as company-specific. The ORTEX short score of 37.7 — in the 42nd percentile for its sector — reflects a relatively benign bearish setup. The EPS surprise factor score ranks in the 80th percentile, and EPS momentum over 90 days sits at the 61st percentile, indicating the earnings revision trend remains positive even if the stock has lagged.
Earnings are the next firm catalyst. The Q3 event is scheduled for October 16. History is instructive here: the most recent print in late July produced a 5.8% single-day gain and a 4.3% five-day follow-through, the strongest one-day reaction in the available history. The print before that, in mid-July, saw the stock fall 4.2% on the day before recovering to roughly flat over five sessions. That alternating pattern — and the magnitude of the moves — suggests the market treats each Blackstone earnings report as a genuine event risk rather than a rubber-stamp. The spread between Oppenheimer's $171 target and Goldman's $127 Neutral target is close to $44, or about 32% of the current price: an unusually wide range of outcomes that makes the Q3 print particularly consequential for determining which analyst camp the stock gravitates toward.
Whether the week's analyst target upgrades get validated or overtaken by macro pressure on alternatives is the question worth tracking between now and October 16.
See the live data behind this article on ORTEX.
Open BX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.